On September 2, the New England Journal of Medicine published the results of a unique trial of a drug combination that showed significant slowing of ALS disease progression. This is the first time an ALS therapy has shown effectiveness in accomplishing more than a reduction of symptoms, opening the door to preventing nerve cell death and offering hope to individuals with ALS and their families.
Hear from the Director of the Sean M. Healey and AMG Center for ALS Merit Cudkowicz, MD, MSc and CENTAUR Trial Lead Investigator Sabrina Paganoni, MD, PhD, as they share details of the trial results and next steps in the treatment process.
Mass General researchers shared information about the trial in a webinar hosted the Northeast ALS Consortium (NEALS) on Sept. 4. A recording is available at NEALS.org.